Edgewise Therapeutics

Boulder, CO · Founded 2017 · CIK 0001710072 · Biotech · Public

Novel small-molecule therapeutics targeting muscle biology for skeletal and cardiac muscle diseases

edgewisetx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$120M
2 Form D · Dec 2020
70 months since last filing
Contracts
—
No federal contracts on record
Patents
40
11 granted · 29 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$25,074,998
Private capital raisedForm D · SEC$95,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2807Seismic Therapeutic, Inc.—$121M
2808TRIM-EDICINE INC——
2809Orna Therapeutics Holdings, LLC—$121M
2810Edgewise Therapeutics—$120M
2811Ensoma—$120M
2812A2 Biotherapeutics—$119M
2813Interius BioTherapeutics—$118M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 5 related persons
  • Kenneth HarrisonDirector
  • Kevin KochDirector · Executive Officer
  • Jonathan RootDirector
  • Alan RussellDirector
  • Peter ThompsonDirector

Patents

USPTO · 11 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.